Advent Life Sciences



Amphista Therapeutics closes £6m funding round

Amphista Therapeutics, a University of Dundee spin-out, has announced a multi-million-pound deal to develop first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins.

Published 7 April 2020

Pheno Therapeutics launches with £5m investment

Pheno Therapeutics, a new drug-discovery spin-out from the University of Edinburgh, has been launched with the backing of Series A funding totalling £5 million from Advent Life Sciences, the Scottish Investment Bank and LifeArc.

Published 18 February 2020